SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Andersson Yvonne)
 

Sökning: WFRF:(Andersson Yvonne) > (2020-2024) > Tailored dose-dense...

Tailored dose-dense versus standard adjuvant chemotherapy for high-risk early breast cancer : end-of-study results of the randomized PANTHER trial

Matikas, Alexios (författare)
Karolinska Institutet,Oncology/Pathology Department, Karolinska Institutet, Stockholm, Sweden; Breast Center, Karolinska Comprehensive Cancer Center, Stockholm, Sweden
Möbus, Volker (författare)
Department of Medicine II, Hematology & Oncology, University of Frankfurt, Frankfurt, Germany
Greil, Richard (författare)
3rd Medical Department, Paracelsus Medical University and Salzburg Cancer Research Institute, Cancer Cluster Salzburg and AGMT, Salzburg, Austria
visa fler...
Andersson, Anne, 1966- (författare)
Umeå universitet,Onkologi
Steger, Günther G. (författare)
Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria
Untch, Michael (författare)
Helios Klinikum Berlin-Buch, Berlin, Germany
Fornander, Tommy (författare)
Oncology/Pathology Department, Karolinska Institutet, Stockholm, Sweden
Malmström, Per (författare)
Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden; Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden
Schmatloch, Sabine (författare)
Elisabeth Hospital, Kassel, Germany
Johansson, Hemming (författare)
Oncology/Pathology Department, Karolinska Institutet, Stockholm, Sweden
Hellström, Mats (författare)
Breast Center, Karolinska Comprehensive Cancer Center, Stockholm, Sweden
Brandberg, Yvonne (författare)
Oncology/Pathology Department, Karolinska Institutet, Stockholm, Sweden
Gnant, Michael (författare)
Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
Loibl, Sibylle (författare)
German Breast Group, Neu-Isenburg, Germany
Foukakis, Theodoros (författare)
Oncology/Pathology Department, Karolinska Institutet, Stockholm, Sweden; Breast Center, Karolinska Comprehensive Cancer Center, Stockholm, Sweden
Bergh, Jonas (författare)
Karolinska Institutet,Oncology/Pathology Department, Karolinska Institutet, Stockholm, Sweden; Breast Center, Karolinska Comprehensive Cancer Center, Stockholm, Sweden
visa färre...
 (creator_code:org_t)
2024
2024
Engelska.
Ingår i: Journal of Clinical Oncology. - 0732-183X .- 1527-7755.
Relaterad länk:
https://doi.org/10.1...
visa fler...
https://umu.diva-por... (primary) (Raw object)
https://urn.kb.se/re...
https://doi.org/10.1...
http://kipublication...
visa färre...
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.Although dose-dense adjuvant chemotherapy administered once every 2 weeks leads to superior outcomes compared with standard regimens once every 3 weeks, the observed improvement is largely limited to studies using the suboptimal paclitaxel schedule once every 3 weeks as control. PANTHER is an international phase III trial which compared sequential epirubicin/cyclophosphamide and docetaxel administered either once every 2 or once every 3 weeks, with tailored dosing at the dose-dense schedule according to hematologic toxicity. In this end-of-study analysis, the median follow-up was 10.3 years. Compared with standard adjuvant chemotherapy, dose-dense treatment improved breast cancer recurrence-free survival (hazard ratio [HR], 0.80 [95% CI, 0.65 to 0.98]; P = .030), event-free survival (HR, 0.78 [95% CI, 0.65 to 0.94]; P = .009), and distant disease-free survival (HR, 0.79 [95% CI, 0.64 to 0.98]; P = .030) while the improvement in overall survival was not statistically significant (HR, 0.82 [95% CI, 0.65 to 1.04]; P = .109). To our knowledge, this is the first trial that confirms the benefit of a dose-dense regimen over a control regimen containing docetaxel once every 3 weeks.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy